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Abstract 
The Trans-Pacific Partnership (“TPP”) Agreement mandates member states to 
implement a patent linkage system vested in Article 18.53. To successfully join the 
TPP Agreement, Taiwan has begun the legislation of a patent linkage system by 
proposing an amendment for the Pharmaceutical Affairs Act. Article 18.53 requires a 
member either to adopt a notification mechanism under Paragraph 1 or to stay the 
issuance of marketing approval under Paragraph 2. But, Taiwan’s proposal includes 
both measures. Taiwan’ patent linkage system allows a pioneer drug company to 
register patents claiming (a) a material; (b) a combination or formula; or (c) 
pharmaceutical use. The scope of patentees who may benefit from the mechanism is 
larger than what is required. In addition, the system requires a generic drug company 
to notify the patentee at the time of filing the drug application if the generic drug 
company asserts invalidity or non-infringement which the generic drug company must 
prove. Furthermore, the health authority is allowed to stay the issuance of a generic 
drug permit while the patentee is suing the generic drug company in the court. 
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I. INTRODUCTION 
The Trans-Pacific Partnership (“TPP”) Agreement was signed on February 4, 2016 
in Auckland, New Zealand.1 Twelve countries, including Australia, Brunei, Canada, 
Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States and 
Vietnam, were involved in this multilateral free trade agreement (“FTA”).2 
Like many FTAs,3 the TPP Agreement has an intellectual property chapter which 
is Chapter 18.4 Chapter 18 includes many provisions collectively setting a standard 
beyond the Agreement on Trade-Related Aspects of Intellectual Property Rights 
(“TRIPS Agreement”).5 Article 18.53 of the TPP Agreement is a highly-criticized 
                                                          
 1 See Rebecca Howard, Trans-Pacific Partnership Trade Deal Signed, but Years of 
Negotiations Still to Come, REUTERS, Feb. 4, 2016, http://www.reuters.com/article/us-trade-tpp-
idUSKCN0VD08S (last visited Oct. 16, 2016); see also Kevin E. Noonan, The Trans-Pacific 
Partnership the Future of Global Trade or A Corporate Conspiracy Against Workers?, 8 
LANDSLIDE 32, 32 (2016).  
 2 See Howard, supra note 1.  
 3 See Ping-Hsun Chen, Cross-Straits Economic Cooperation Framework Agreement, 
Cross-Strait Agreement on Intellectual Property Right Protection and Cooperation, and 
Implications of One-China, 36 HOUS. J. INT’L L. 59, 66-67 (2014). 
 4 See TPP Final Table of Contents, Office of the United States Trade Representative, 
https://ustr.gov/trade-agreements/free-trade-agreements/trans-pacific-partnership/tpp-full-text 
(last visited Oct. 16, 2016).  
 5 See Rupali Francesca Samuel, Drawn Up in Secret, the TPP’s Text Helps Big Pharma 
Put Patents Over Patients, THE WIRE, (Nov. 16, 2015), http://thewire.in/15571/drawn-up-in-
secret-the-tpps-text-helps-big-pharma-put-patents-over-patients/ (last visited Oct. 16, 2016).  
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provision that relates to “patent linkage.”6 “Patent linkage” originates from the Hatch-
Waxman Act of 1984.7 The Hatch-Waxman Act established the Abbreviated New 
Drug Application (“ANDA”) system which allows a pharmaceutical company to 
apply for a marketing approval of a generic version of a previously-approved drug 
without going through a full-scale experiment concerning the safety and efficacy of 
the generic drug.8 But, to compromise with the benefits of pioneer drug companies, 
the Hatch-Waxman Act created a cause of action for pioneer drug companies to sue 
those generic drug companies for patent infringement simply because of the filing of 
an ANDA.9 Australia, Canada, and Singapore also have a patent linkage system.10 
While the TPP Agreement is under the national approval proceeding in each 
member state, Taiwan is eager to join the TPP Agreement.11 Among other things, the 
Executive Yuan12 announced a proposed amendment of the Pharmaceutical Affairs 
                                                          
 6 See Brook K. Baker & Katrina Geddes, Corporate Power Unbound: Investor-State 
Arbitration of IP Monopolies on Medicines-Eli Lilly v. Canada and the Trans-Pacific 
Partnership Agreement, 23 J. INTELL. PROP. L. 1, 10, 10 n.43 (2015). 
 7 See Robert A. Armitage, The Hatch-Waxman Act: A Path Forward for Making It More 
Modern, 40 WM. MITCHELL L. REV. 1200, 1201-03, 1235 (2014). 
 8 See Quincy (Ping-Hsun) Chen, Destroying A Pharmaceutical Patent for Saving Lives?: 
A Case Study of Sanofi-Synthelabo v. Apotex, Inc., 21 ALB. L.J. SCI. & TECH. 125, 136 (2011). 
 9 See id. at 139-40. 
 10 See, e.g., Thomas A Faunce and Joel Lexchin, ‘Linkage’ Pharmaceutical Evergreening 
in Canada and Australia, AUSTL. & N.Z. HEALTH POL’Y, June 1, 2007, available at 
http://www.anzhealthpolicy.com/content/4/1/8 (last visited Oct. 16, 2016). 
 11 See Tsai Appeals to US Leaders for TPP Support, TAIPEI TIMES, (Jul. 3, 2016), 
http://www.taipeitimes.com/News/taiwan/archives/2016/07/03/2003650248. Because the 
United States recently elected a new President, Donald Trump, who aggressively opposed the 
TPP Agreement during the campaign, the future of the TPP Agreement is very negative. See, 
e.g., Tim Worstall, With Trump’'s Election the TPP Probably is Dead, Yes - As is the TTIP, 
FORBES, (Nov. 11, 2016_), http://www.forbes.com/sites/timworstall/2016/11/11/with-trumps-
election-the-tpp-probably-is-dead-yes-as-is-the-ttip/#18a9a7845b80 ; Sam Buckingham-Jones, 
Trans-Pacific Partnership Deal not Our Only Trade Option, Steve Ciobo Says, THE 
AUSTRALIAN, (Nov. 13, 2016), http://www.theaustralian.com.au/national-affairs/foreign-
affairs/transpacific-partnership-deal-not-our-only-trade-option-steve-ciobo-says/news-
story/d0fa129210d05475a9bcd15df114539b. On the other hand, Japan’s intent to approve the 
TPP Agreement right after the U.S. presidential election makes the issue more complicate. See, 
e.g., Japan’s Parliament Approves TPP Deal, Labeled ‘Disaster’ by Trump, RT, (Nov. 10, 
2016), https://www.rt.com/news/366367-japan-tpp-trump-china/; Japan Lawmakers Vote to 
Ratify TPP, WALL STREET JOURNAL, (Nov. 4, 2016), http://www.wsj.com/articles/japan-
lawmakers-vote-to-ratify-tpp-1478256900.  
 12 The Executive Yuan is the executive branch of the Taiwan Government. 
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Act13 (“PAA”) on August 4, 2016.14 The Proposed Amendment adds Chapter 4-1 
governing a patent linkage system for generic drug permit (“GDP”) applications.15 
The Proposed Amendment has been submitted to the Legislative Yuan.16 The 
proposed patent linkage system forces a generic drug company to confront with patent 
law suits brought by a pioneer drug company. To do so, the Executive Yuan also 
introduced an amendment of the Patent Act.17 The Patent Act Amendment provides a 
cause of action for a pioneer company to sue a generic drug company if the latter 
company files a GDP application.18 
This article is intended to explore the Proposed Amendment to figure out whether 
the Proposed Amendment follows Article 18.53 of the TPP Agreement or goes beyond 
the minimal protection on pioneer drug companies. To answer that question, it is 
necessary to interpret Article 18.53 to figure out the scope of protection. In this paper, 
Part II critically reviews Article 18.53 in light of the international law principles of 
treaty interpretation under Article 31(1) of the Vienna convention on the Law of 
Treaties (“VCLT”). Then, Part III introduces the current Pharmaceutical Affairs Act 
with respect to new drug applications and generic drug applications. The topics cover 
test data submission, patent information submission, and test data protection. Finally, 
Part IV analyzes the Proposed Amendment. The analysis covers the new system of 
patent information submission, notification mechanism, administrative action, and 
anti-competition. 
                                                          
 13 It is also known as “yao-shi fa” (藥事法) in Mandarin. The official English text of the 
Pharmaceutical Affairs Act (“PAA”) can be found at 
http://law.moj.gov.tw/Eng/LawClass/LawAll.aspx?PCode=L0030001, while the Mandarin 
version can be found at http://law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0030001. The 
current Pharmaceutical Affairs Act became effective on December 2, 2015 by Presidential 
Order hua zong yi yi No. 10400140921 (總統華總一義字第10400140921號令). When 
referring to any provisions of the PAA, this paper cites or quotes the official English text unless 
the author feels that the official translation cannot reflect the meaning of a provision. 
 14 See Executive Yuan, Taiwan, The Executive Yuan Committee Passed a Proposed 
Amendment of the Pharmaceutical Affairs Act (Press Release), 
http://www.ey.gov.tw/News_Content2.aspx?n=F8BAEBE9491FC830&s=B7A2785C56246F
BA (in Mandarin) (last visited Oct. 16, 2016).  
 15 See Crystal J. Chen, Draft Amendment to Pharmaceutical Affairs Act Introduces Patent 
Linkage System and Revised Data Exclusivity, LEXOLOGY, (Oct. 31, 2016), 
http://www.lexology.com/library/detail.aspx?g=b50d0454-39c9-4694-a827-45d6d5acfe8d. 
 16 See Abraham Gerber, NHI Costs Would Rise with Law Changes: Opponents, TAIPEI 
TIMES, (Sept. 24, 2016), 
http://www.taipeitimes.com/News/taiwan/archives/2016/09/24/2003655834. The Proposed 
Amendment can be downloaded at 
http://lci.ly.gov.tw/LyLCEW/agenda1/02/pdf/09/02/01/LCEWA01_090201_00043.pdf. 
 17 See Crystal J. Chen, TIPO Proposed to Amend IP Laws Echoing Trans-Pacific 
Partnership Agreement, LEXOLOGY, (Aug. 5, 2016), 
http://www.lexology.com/library/detail.aspx?g=9a7b1ae4-2b62-42ab-8382-23a01f24e6f9 
[hereinafter, Chen, TIPO Proposed]. 
 18 See Chen, TIPO Proposed, supra note 17; see also Patent Act Amendment art. 60-1, para. 
1. The Patent Act Amendment can be downloaded at 
http://lci.ly.gov.tw/LyLCEW/agenda1/02/pdf/09/02/01/LCEWA01_090201_00044.pdf (in 
Mandarin). 
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II. TPP IP CHAPTER AND PATENT LINKAGE CLAUSE 
Part II discusses the prerequisite of patent linkage and analyzes three requirements 
of the patent linkage system under the TPP Agreement. The analysis follows Article 
31(1) of the VCLT which provides that “[a] treaty shall be interpreted in good faith in 
accordance with the ordinary meaning to be given to the terms of the treaty in their 
context and in the light of its object and purpose.”19 Accordingly, the TRIPS 
Agreement and Declaration on TRIPS and Public Health are interpretation tools.20 On 
the other hand, Article 31(2) of the VCLT further provides that “[t]he context for the 
purpose of the interpretation of a treaty shall comprise, in addition to the text, 
including its preamble and annexes: (a) any agreement relating to the treaty which was 
made between all the parties in connexion with the conclusion of the treaty[,]21 but 
this paper does not consider those agreements made during the negotiations for the 
TPP Agreement because of the lack of publicly-accessible information. 
 
A. Prerequisite of Patent Linkage 
Article 18.53(1) sets only one condition as to when a member state shall provide a 
patent linkage system. Paragraph 1 recites:  
 
[A] Party permits, as a condition of approving the marketing of a 
pharmaceutical product, persons, other than the person originally 
submitting the safety and efficacy information, to rely on evidence or 
information concerning the safety and efficacy of a product that was 
previously approved, such as evidence of prior marketing approval by the 
Party or in another territory[.]22 
 
The condition has three elements. First, the marketing approval law requests an 
applicant to submit the safety and efficacy information of a pharmaceutical product.23 
Second, an applicant may be permitted to rely on the safety and efficacy information 
previously submitted by other applicant.24 Third, the previously-submitted safety and 
efficacy information was used for the marketing approval of such prior applicant’s 
product.25 
                                                          
 19 Vienna Convention on the Law of Treaties art. 31(1) (1969) (emphasis added). 
 20 See TPP Agreement art. 18.6(1) (“The Parties affirm their commitment to the Declaration 
on TRIPS and 
Public Health.”). 
 21 Vienna Convention on the Law of Treaties art. 31(2) (1969) (emphasis added). 
 22 TPP Agreement art. 18.53(1). 
 23 TPP Agreement art. 18.53(1)(a). 
 24 TPP Agreement art. 18.53(1)(b). 
 25 TPP Agreement art. 18.53(1)(c). 
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Therefore, the patent linkage system is not required if an applicant does not rely 
on any previously-submitted safety and efficacy information, or if an applicant relies 
on the safety and efficacy information of a pharmaceutical product that is not 
previously approved. 
The patent linkage system under the TPP Agreement must be understood in the 
context of data protection. Patent linkage is applied after the term of test data 
protection. Under Article 18.50(1), if a previously-approved product is a new 
pharmaceutical product, any latter applicant is not permitted to rely on the safety and 
efficacy information of such previously-approved product for at least five years from 
the date of marketing approval of such previously-approved product. Under Article 
18.52, a “new pharmaceutical product” in Article 18.50(1) means “a pharmaceutical 
product that does not contain a chemical entity that has been previously approved.”26 
The term of test data protection for at least five years also applies to a new 
pharmaceutical product defined in Article 18.50(2)(b) as a pharmaceutical product that 
contains “a chemical entity that has not previously approved[.]”27 
Under Article 18.51, the term of test data protection is at least eight years for a 
new pharmaceutical product “that is or contains a biologic,”28 or at least five years if 
other measures are also taken.29 A “biologic” is defined in Article 18.51(2) as to 
include “at a minimum, a product that is, or, alternatively, contains, a protein produced 
using biotechnology processes, for use in human beings for the prevention, treatment, 
or cure of a disease or condition.”30 
After the term of test data protection, a member state may permit an applicant to 
rely on the safety and efficacy information of a previously-approved product. At that 
time, such applicant is subject to the patent linkage system. Therefore, the patent 
linkage system functions as an extension of data protection. 
It should be noted that Article 18.53(1) does not require “a product that was 
previously approved” to be a new pharmaceutical product as Articles 18.50 and 18.51 
do.31 But, in the context of generic drug applications, a person who originally 
submitted the safety and efficacy information that following generic drug companies 
rely on is more likely to be a right holder of the patents claiming the previously-
approved product.32 
 
                                                          
 26 TPP Agreement art. 18.52 (emphasis added). 
 27 TPP Agreement art. 18.50(2)(b). 
 28 See TPP Agreement art. 18.51(1)(a). 
 29 See TPP Agreement art. 18.51(1)(b). “Other measures” are not defined in the same 
provision. 
 30 TPP Agreement art. 18.51(2). 
 31 TPP Agreement art. 18.53(1). 
 32 See Mark Gibson, Introduction and Perspective, in PHARMACEUTICAL PREFORMULATION 
AND FORMULATION 1, 5 (Mark Gibson ed., Informa Healthcare USA 2009), available at 
http://basijmed.ir/public/vimb/books/foreign%20books/Biopharmaceutical8.pdf (last visited 
Oct. 16, 2016).  
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B. Patent Linkage System 
1. Notification Requirement 
Article 18.53(1) sets three requirements for a patent linkage system. First, under 
Article 18.53(1)(a), a member state must establish “a system to provide notice to a 
patent holder or to allow for a patent holder to be notified prior to the marketing of 
such a pharmaceutical product, that such other person is seeking to market that product 
during the term of an applicable patent claiming the approved product or its approved 
method of use[.]”33 A member state may choose to treat a “patent holder” broadly as 
“a patent licensee or the authorized holder of marketing approval.”34  
This notification requirement mandates the drug approval authority of a member 
state to establish a mechanism to inform a patent holder of marketing approval of a 
product associated with her patent. But, to be an eligible patent holder, the patent in 
question must claim the to-be-approved product or to-be-approved treatment.35 In 
other words, the patent must be a pharmaceutical formula or a treatment through use 
of such pharmaceutical formula. However, in a member state which excludes from 
patentability “diagnostic, therapeutic and surgical methods for the treatment of 
humans” under Article 27(3)(a) of the TRIPS Agreement,36 an eligible patent may 
only be a patent claiming a pharmaceutical formula. 
A patent claiming a pharmaceutical formula has a specific meaning. A 
pharmaceutical formula is a composition of active pharmaceutical ingredients and 
excipients.37 “Excipients” include four categories: (a) substances that “aid in the 
processing of the drug delivery system during its manufacture”; (b) substances that 
“protect, support or enhance stability, bioavailability or patient acceptability”; (c) 
substances that “assist in product identification”; (d) substances that “enhance any 
other attribute of the overall safety, effectiveness or delivery of the drug during storage 
or use.”38 Thus, for purposes of patent linkage, an eligible drug patent must claim not 
only active pharmaceutical ingredients and excipients of the previously-approved 
drug, but also dosage forms thereof.39  
 
                                                          
 33 TPP Agreement art. 18.53(1)(a) (emphasis added). 
 34 TPP Agreement chap. 18 n. 62. 
 35 Id. 
 36 See TRIPS Agreement art. 27(3)(a) (2017). 
 37 See Nishath Fathima et al., Drug-Excipient Interaction and its Importance in Dosage 
Form Development, 1 JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE 66, 66 (2011), available 
at http://www.japsonline.com/admin/php/uploads/125_pdf.pdf (last visited Oct. 16, 2016).  
 38 See INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL, THE IPEC EXCIPIENT 
COMPOSITION GUIDE 2 (2009), available at http://ipec-
europe.org/UPLOADS/IPECCompositionGuidefinal.pdf (last visited Oct. 16, 2016).  
 39 See Carlos Correa, Guidelines for the Examination of Pharmaceutical Patents: 
Developing a Public Health Perspective 6-9 (University of Buenos Aires, Working Paper 2006), 
available at http://www.ufrgs.br/antropi/lib/exe/fetch.php?media=correa_pharmaceutical-
patents-guidelines.pdf (last visited Oct. 16, 2016).  
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2. Timing Requirement 
The second requirement is the timing requirement. Article 18.53(1)(b) mandates a 
member state to provide “adequate time and opportunity for such a patent holder to 
seek, prior to the marketing of an allegedly infringing product, available remedies in 
subparagraph (c)[.]”40 Three aspects may be added to the interpretation of Article 
18.53(1)(b). First, the use of “seek” indicates that only a right to seek subparagraph 
(c) remedies is required, but actual granting of such remedies in every case is not 
mandatory. Second, the phrase “prior to the marketing of an allegedly infringing 
product” indicates that a right to seek available remedies in subparagraph (c) may be 
provided before the authority grants marketing approval or between the issue of 
marketing approval and actual marketing by the approval holder. That is, it is not 
required to stay the proceeding of marketing approval review before the patentee seeks 
mandatory remedies. Third, the “adequate time and opportunity” factor must be 
considered. Thus, it may not be adequate to avail the right to seek the required 
remedies just before the approval holder starts to market the allegedly infringing 
product.  
 
3. “Procedure and Remedy” Requirement 
The last requirement is the “procedure and remedy” requirement. Article 
18.53(1)(c) demands “procedures, such as judicial or administrative proceedings, and 
expeditious remedies, such as preliminary injunctions or equivalent effective 
provisional measures, for the timely resolution of disputes concerning the validity or 
infringement of an applicable patent claiming an approved pharmaceutical product or 
its approved method of use.”41 That is, a member state must provide judicial or 
administrative proceedings. In those proceedings, an eligible patentee may move for 
either preliminary injunctions or equivalent effective provisional measures. The 
proceedings must be timely to resolve the issue of validity or infringement. However, 
a few questions remain. 
The first question is whether there exists any infringing act during the marketing 
approval proceeding. If there is no infringing act, the only dispute will be validity. The 
interpretation of Article 18.53(1)(c) should not go that way. Otherwise, the term 
“infringement” would be void, which unlikely reflects the intent of the TPP 
Agreement. Thus, it is necessary to figure out which act is an infringing act during the 
marketing approval proceeding. 
Under Article 28(1)(a) of the TRIPS Agreement, a patentee has exclusive rights to 
prevent others from making, using, offering for sale, selling, or importing for these 
purposes, her patented product.42 Or, under Article 28(1)(b) of the TRIPS Agreement, 
a holder of a process patent has a right to exclude others from using her patented 
                                                          
 40 TPP Agreement art. 18.53(1)(b) (emphasis added). 
 41 TPP Agreement art. 18.53(1)(c). 
 42 See TRIPS Agreement art. 28(1)(a) (“A patent shall confer on its owner the following 
exclusive rights: (a) where the subject matter of a patent is a product, to prevent third parties 
not having the owner's consent from the acts of: making, using, offering for sale, selling, or 
importing for these purposes that product[.]”). 
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process.43 Because the TPP Agreement does not create any new exclusive rights, the 
rights of an eligible patent holder under the TPP Agreement are limited to Article 
28(1) of the TRIPS Agreement. In addition, seeking a marketing approval may not be 
an act of infringement under Article 18.49 of the TPP Agreement.44 Therefore, the 
question becomes whether acquiring a marketing approval constitutes infringement.  
A marketing approval holder has a right to market his approved drug. But, that is 
not equal to infringement. Marketing may mean advertising, events, knocking on 
doors, or direct mail.45 In any case, a drug company markets its product because it 
wants to sell the product to targeted customers, such as doctors, hospitals, pharmacists, 
and patients. If a drug company merely promotes the availability of its product, there 
may be no infringement. But, if prices are in the marketing materials, such marketing 
act is more likely to constitute an “offer for sale” so as to infringe the patent.46 It is 
evident that a marketing approval holder will eventually offer a price of its drug to 
potential buyers. As a result, there is a potential threat to the patent holder. A timely 
resolution of the infringement issue is required when a marketing approval is granted. 
The issue of validity must be accompanied. Without a valid patent, there will be no 
infringement. 
The second question is what “timely resolution” means. Although the TPP 
Agreement does not provide any clue, the phrase may be understood in light of Article 
42 of the TRIPS Agreement. Article 42 requires that “[d]efendants shall have the right 
to written notice which is timely and contains sufficient detail, including the basis of 
the claims.”47 Article 42 also provides that all parties “shall be duly entitled to 
substantiate their claims and to present all relevant evidence.”48 Therefore, the 
implementation of “timely resolution” should consider not only the interests of a 
patent holder, but also a marketing approval holder’s right of due process.  
The last question is the scope of “expeditious remedies.” Article 18.53(1)(c) 
specifies “preliminary injunctions or equivalent effective provisional measures” as 
two categories of expeditious remedies. The use of “preliminary” and “provisional” 
indicates that those injunctions or measures are imposed before a court issues a final 
decision regarding whether the patent is infringed or whether the patent is valid. But, 
                                                          
 43 See TRIPS Agreement art. 28(1)(b) (“A patent shall confer on its owner the following 
exclusive rights: … (b) where the subject matter of a patent is a process, to prevent third parties 
not having the owner’s consent from the act of using the process, and from the acts of: using, 
offering for sale, selling, or importing for these purposes at least the product obtained directly 
by that process.”). 
 44 See TPP Agreement art. 18.49 (“Without prejudice to the scope of, and consistent with, 
Article 18.40 (Exceptions), each Party shall adopt or maintain a regulatory review exception for 
pharmaceutical products.”). 
 45 See JOHN BURNETT, CORE CONCEPTS OF MARKETING 3 (2008), available at 
http://www.saylor.org/site/wp-content/uploads/2012/11/Core-Concepts-of-Marketing.pdf (last 
visited Oct. 16, 2016).  
 46 See 3D Sys., Inc. v. Aarotech Labs., Inc., 160 F.3d 1373, 1379 (1998) (“As a matter of 
federal statutory construction, the price quotation letters can be regarded as ‘offer[s] to sell’ 
under § 271 based on the substance conveyed in the letters, i.e., a description of the allegedly 
infringing merchandise and the price at which it can be purchased.” (alterations in original)). 
 47 TRIPS Agreement art. 42. 
 48 Id.  
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whether those expeditious remedies are mandatory is unclear. What factor has to be 
included in the consideration of those expeditious remedies is not listed in Article 
18.53.  
The availability of “expeditious remedies” may be determined in view of Article 
18.50(3) of the TPP Agreement. Article 18.50(3) provides that a member state “may 
take measures to protect public health in accordance with: (a) the Declaration on 
TRIPS and Public Health[.]”49 Although the Doha Declaration on TRIPS and Public 
Health (hereinafter, “Doha Declaration”) focuses on the issue of compulsory 
licensing,50 it emphases a balance between the importance of intellectual property 
protection for new drug development and the concerns on drug prices.51 Thus, public 
interests should be taken into consideration when expeditious remedies are 
implemented. This norm is also adopted in the United States as the Federal Circuit has 
held that “[t]o obtain a preliminary injunction, a party must show ‘that it is likely to 
succeed on the merits, that it is likely to suffer irreparable harm in the absence of 
preliminary relief, that the balance of equities tips in its favor, and that an injunction 
is in the public interest.’”52 
In conclusion, the “procedure and remedy” requirement mandates procedures and 
expeditious remedies for a patent holder to resolve the issue of valid or infringement 
of her patent claiming the approved drug when the marketing approval is granted. But, 
the procedures must balance the interests of the patent holder and marketing approval 
holder. Public health must also be considered. 
 
C. Alternative to the Patent Linkage System 
Article 18.53(2) of the TPP Agreement establishes an alternative system to the 
patent linkage system under Article 18.53(1). Article 18.53(2) provides: 
 
As an alternative to paragraph 1, a Party shall instead adopt or maintain a 
system other than judicial proceedings that precludes, based upon patent-
related information submitted to the marketing approval authority by a 
patent holder or the applicant for marketing approval, or based on direct 
coordination between the marketing approval authority and the patent 
office, the issuance of marketing approval to any third person seeking to 
market a pharmaceutical product subject to a patent claiming that product, 
unless by consent or acquiescence of the patent holder.53 
 
                                                          
 49 TPP Agreement art. 18.50(3)(a). 
 50 See Declaration on the TRIPS Agreement and Public Health, World Trade Organization, 
DOHA WTO Ministerial (Nov. 14, 2001), ¶5, 41 I.L.M. 755 (2002) [hereinafter Doha 
Declaration], https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm 
(last visited Oct. 16, 2016).  
 51 See Id. at ¶4. 
 52 Luminara Worldwide, LLC v. Liown Elecs. Co., 814 F.3d 1343, 1352 (2016) (original 
alterations omitted). 
 53 TPP Agreement art. 18.53(2) (emphasis added). 
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The phrase “an alternative to paragraph 1” indicates that a system under Article 
18.53(2) is not mandatory but optional. The system is defined as a non-judicial 
proceeding, so it has to be an administrative proceeding. By stating that a drug 
authority “precludes, … , the issuance of marketing approval,” Article 18.53(2) does 
not require the authority to deny or reject the application for marketing approval. 
“Preclude” means “to make (something) impossible,” “to prevent (something) from 
happening,” or “to prevent (someone) from doing something.”54 Thus, Article 
18.53(2) may merely require a stay of issuing a marketing approval. 
Under Article 18.53(2), preclusion of the issuance of marketing approval may be 
based on the “patent-related information” submitted by a patent holder or marketing 
approval applicant. But, the definition of “patent-related information” is unclear. It 
may mean at least the information of patents as required in Article 18.53(1). In 
addition, preclusion may be based on “direct coordination” between the drug authority 
and patent authority. The second basis is more ambiguous because the TPP Agreement 
does not give any instruction on how two authorities may work together to conclude 
a decision of preclusion. Therefore, it is more difficult to implement Article 18.53(2) 
than Article 18.53(1). 
It should be noted that by providing a system for a drug authority to preclude the 
issuance of marketing approval, Article 18.53(2) reaffirms that the timing for initiating 
the patent linkage system under Article 18.53(1) is the time of issuing a marketing 
approval. Otherwise, Article 18.53(2) is not distinct enough as to be an alternative to 
Article 18.53(1). 
 
D. Summary 
While the exact meaning of the “patent linkage” provision under the TPP 
Agreement is uncertain, the above analysis may provide some insights of how to 
implement the provision as follows: 
(1) A patent linkage system is required only when an applicant for marketing 
approval relies on the safety and efficacy information of a previously-approved drug. 
(2) To enjoy the benefits of patent linkage, an eligible patent holder must own a 
patent claiming a pharmaceutical formulation or method for using such 
pharmaceutical formulation. But, in a member state adopting Article 27(3)(a) of the 
TRIPS Agreement, only a person who holds a patent for a pharmaceutical formulation 
is eligible. 
(3) A patent holder must be informed of the marketing approval of a drug covered 
by her eligible patent when the drug authority issues the approval. 
(4) A procedure for the timely resolution of infringement or validity of the patent-
in-suit may be an administrative or judicial procedure. While the interests of a patentee 
are primarily concerned with, the procedure must consider a marketing approval 
holder’s right of due process. 
(5) A right to seek expeditious remedies, such as preliminary injunctions or 
equivalent effective provisional measures, is required. But, the grant of such remedies 
must consider public health issues. 
(6) An alternative administrative procedure may be provided where the drug 
authority may preclude the issuance of marketing approval. Preclusion may be based 
                                                          
 54 See MERIAM-WEBSTER, http://www.merriam-webster.com/dictionary/preclude (last 
visited Oct. 16, 2016).  
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on the patent-related information submitted by either a patent holder or marketing 
approval holder. The coordination between the drug authority and patent authority 
may also be a basis for preclusion. 
 
III. DRUG PERMIT APPLICATION UNDER THE PHARMACEUTICAL AFFAIRS ACT 
A. Drug Permit 
The Pharmaceutical Affairs Act (“PAA”) is a multi-task law governing drugs, 
medical devices, pharmaceutical companies, pharmacies and other relevant matters.55 
The PAA is administrated by the Food and Drug Administration (hereinafter, “Taiwan 
FDA”).56 Chapter 4 of the PAA regulates the proceedings of registration and market 
approval of medicaments. Article 39 specifically provides the proceeding of approval 
of a “drug permit” (藥品許可證, yao-pin xu-ke zheng; hereinafter, “DP”).57 Paragraph 
4 of Article 39 authorizes the Ministry of Health and Welfare to promulgate the 
Regulations for Registration of Medicinal Products58 (“Regulations”) to review a 
DP.59 Without a DP, a company cannot manufacture or import drugs.60 An unlicensed 
                                                          
 55 See PAA art. 1, para. 2 (“The term ‘pharmaceutical affairs’ used in the preceding 
Paragraph shall refer to medicaments, pharmaceutical firms, pharmacies and other relevant 
matters.”); art. 4 (“The term ‘medicaments’ as used in this Act shall refer to drugs and medical 
devices.”). 
 56 See  About FDA, Food and Drug Administration, Ministry of Health and Wealth (June 6, 
2006)  http://www.fda.gov.tw/EN/aboutFDAContent.aspx?id=17&chk=ec07b726-f665-4825-
ba5a-7d2387a299ad (last visited Oct. 16, 2016).  
 57 See PAA art. 39, para. 1 (“ For the manufacturing and import of drugs, information 
concerning the ingredients, source of active pharmaceutical ingredients, specifications, 
functions, summary of manufacturing process, and the specification and method of testing, as 
well as other related information and certificates, accompanied by labels and use instructions in 
the original and Chinese languages, and samples, together with the fee paid, shall be filed with 
the central competent health authority for registration and market approval. No manufacturing 
or importation of such drugs shall be allowed until a drug permit license is approved and 
issued.”). 
 58 It is also known as “yao-pin cha-yan deng-ji shen-cha zhun-ze” (藥品查驗登記審查準
則) in Mandarin. The official English text of the Regulations for Registration of Medicinal 
Products (“Regulations”) can be found at 
http://law.moj.gov.tw/Eng/LawClass/LawContent.aspx?PCODE=L0030057, while the 
Mandarin version can be found at 
http://law.moj.gov.tw/LawClass/LawContent.aspx?PCODE=L0030057. 
 59 See PAA art. 39, para. 4 (“The application criteria, review procedure, approval criteria, 
and other matters to be complied with shall be established in the Regulations for Registration 
of Medicinal Products by the central competent health authority.”). 
 60 See Id. at ⁋ 1. 
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drug is considered a fake or counterfeit drug.61 A person who manufactures, imports, 
or sells unlicensed drugs is criminally liable.62  
 
B. Submission of Test Data for a New Drug 
A “new drug” is defined in Article 7 of the PAA as “a drug which can be 
recognized through the examination of the central healthcare authority as a new 
compound, composition with a new therapeutic effect, or dosage form with a new 
administration.”63 Article 38-1 of the Regulations requires a “new drug permit” 
(“NDP”) applicant for a new compound to submit test data of either of two 
categories.64 The first-category data comes from Phase I conducted during the research 
period in Taiwan and Phase III simultaneously conducted in a foreign country.65 The 
second-category data comes from Phase II and Phase III conducted simultaneously in 
Taiwan and foreign country.66 The Regulations also provide the experimental 
requirements for Phases I, II, and III.67 Phase I is considered experimental in its nature 
and requires a pharmacokinetics study or pharmacodynamics study.68 In both studies, 
the number of tested people is at least ten in principle.69 Phase II is clinical testing 
where the number of tested people is at least twenty in principle.70 Phase III is known 
as a pivotal trial where the number of tested people is at least eighty in principle so as 
to sufficiently show that the test result in Taiwan is similar to that in the foreign 
country.71 The testing conditions of Phases I, II, or III may be modified by the Taiwan 
FDA.72 Tested people must be selected from Taiwanese people. 
Alternatively, Article 38-2 of the Regulations allows an applicant to rely on drug 
approval issued by Germany, United States, United Kingdom, France, Japan, 
Switzerland, Canada, Australia, Belgium, or Sweden.73 But, the applicant is still 
required to submit clinical testing data of Phases I, II, and III.74 Phase I under Article 
                                                          
 61 See Id. art. 20 (“The term ‘counterfeit drugs’ as used in this Act shall refer to the drugs 
which are found to fall within any of the following circumstances after inspection or testing: 1. 
The drugs are manufactured without prior approval[.]”). 
 62 See Id. arts. 82, 83. 
 63 Id. art. 7. 
 64 See Regulations for Registration of Medicinal Products art. 38-1 (“Regulations”). 
 65 See Id. art. 38-1, para. 1. 
 66 See Id. 
 67 See Id. 38-1, para. 2. 
 68 See Id. 
 69 See Id. 
 70 See Id. 
 71 See Id. 
 72 See Id. 
 73 See Id. art. 38-2, para. 1. 
 74 See Id. art. 38-2, para. 2. 
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38-2 is the same as Phase I under Article 38-1.75 Phases II & III under Article 38-2 
should be conducted in medical centers of multiple countries, but the number of tested 
Taiwanese people must meet either of two conditions.76 The first condition requires 
that the number for Phase II is at least twenty in principle and that number for Phase 
III is at least eighty in principle.77 The second condition requires in both Phase II and 
Phase III, the number of tested Taiwanese people should amount to at least ten percent 
of the total tested people around the different medical centers.78  
In addition, Article 38-2 of the Regulations requires a second type of Phase III 
clinical data.79 While the second type should be conducted in medical centers of 
multiple countries, the countries must include one of Germany, United States, United 
Kingdom, France, Japan, Switzerland, Canada, Australia, Belgium, and Sweden.80 If 
the number of total tested people is above or equal to two hundreds, the number of 
Taiwanese tested people should be at least thirty in principle or amount to at least five 
percent of the total tested people.81 If the number of total tested people is below two 
hundreds, the number of Taiwanese tested people should be at least ten in principle.82 
The testing conditions may be modified by the Taiwan FDA.83 Finally, the test report 
for the second type must have been submitted to the Food and Drug Administration of 
the United States and European Medicines Agency of the European Union as a 
reference for drug approval.84 
Under Article 38-3, the testing data required by either Article 38-1 or Article 38-2 
may be waived by the Taiwan FDA.85 But, the authority may require the submission 
of bridging study data.86 
Currently, the examination of a drug permit application is not actually performed 
by the Taiwan FDA. Instead, the Taiwan FDA has delegated its power of examination 
to a non-governmental organization, the Center for Drug Evaluation (“CDE”).87 The 
                                                          
 75 See Id.art. 38-1, para. 2 & art. 38-2, para. 2. 
 76 See Regulations art. 38-2, para. 2. 
 77 See Id. 
 78 See Id. 
 79 See Id. 
 80 See Id. 
 81 See Id. 
 82 See Id. 
 83 See Id. 
 84 See Id. 
 85 See Regulations art. 38-3. 
 86 See Id. 
 87 See About Us, Center for Drug Evaluation, http://www.cde.org.tw/eng/ (“The Center for 
Drug Evaluation (CDE) is a non-government and non-profit organization established by the 
Department of Health (now the Ministry of Health and Welfare, MOHW) to assist the Taiwan 
Food and Drug Administration (TFDA) in performing review of medical products and related 
services.”). 
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Taiwan FDA is an office receiving submissions, while the CDE examines the 
scientific validity of those submissions. 
 
C. Disclosure of Patent Information 
The disclosure of patents or patent applications related to an approved new drug is 
not mandatory under the PAA, while Article 40-2, Paragraph 1 requires the Taiwan 
FDA to publish publicly-disclosed patent numbers or patent application numbers 
submitted by a NDP applicant.88 Because the Taiwan FDA is required to publish the 
patent information of an approved drug, the Taiwan FDA has promulgated “an 
affidavit form of previously-disclosed patent numbers or patent application numbers” 
(已揭露專利字號/案號切結書, yi jie-lu zhuan-li zi-hao or an-hao qie-jie shu).89 In 
principle, a NDP applicant has to file such form when submitting her application for 
drug approval. However, not all applicants follow the Taiwan FDA’s instruction.90 
 
D. Test Data Protection 
Article 40-2 of the PAA provides the protection on test data submitted by previous 
NDP applicants for a new compound.91 If the NDP holder of a previously-approved 
new compound has a marketing approval for the same compound in a foreign country, 
to enjoy the data protection, she must file a NDP application in three years from the 
issuance of her foreign marketing approval.92 Article 40-2, Paragraph 2 prevents a 
latter applicant from relying on the test data of a previously-approved new compound 
for five years from the issuance of the drug permit for such new compound.93 
However, Article 40-2, Paragraph 3 allows a drug permit application for a drug that 
has the same compound, same dosage form, same dosage, and same unit dose as a 
previously-approved drug has possessed.94 But, such Paragraph 3 application is 
permitted only after three years from the issuance of the NDP of such previously-
approved new compound.95 Article 40-2, Paragraph 2 still applies to when a Paragraph 
3 application may rely on the test data of a previously-approved new compound.96  
 
                                                          
 88 See PAA art. 40-2, ⁋1. 
 89 See Wei Shu Yao Zi,  MINISTRY OF HEALTH AND WEALTH ORDER No. 0940330797 (Oct. 
24, 2005), http://www.fda.gov.tw/pda/page01Content.aspx?id=1032&chk=787b7135-d0b9-
467f-b572-9054f9a4af0d&param=pn%3D145. 
 90 See Regulations of Medicament Manufacturer Inspection, Food and Drug Administration, 
Ministry of Health and Welfare,  
http://www.fda.gov.tw/upload/133/2016081809343014308.xlsx.  
 91 PAA Art. 40. 
 92 See Id. art. 40-2, para. 4. 
 93 See Id. art. 40-2, para. 2. 
 94 See Id. art. 40-2, para. 3. 
 95 See Id. 
 96 See Id. 
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E. “Generic Drug Permit” Application 
Although the PAA does not define a “generic drug,” the Regulations do define a 
“generic drug” as a drug that has the same compound, same dosage form, same dosage, 
and same efficacy of a previously-approved drug.97 Therefore, in Article 40-2, 
Paragraph 3 of the PAA, a drug that has the same compound, same dosage form, same 
dosage, and same unit dose as a previously-approved drug may be considered as a 
generic version of such previously-approved drug.98 A Paragraph 3 application is a 
Taiwanese version of a generic drug application. 
However, the PAA does not allow a GDP applicant to rely on her own test data. 
The Proposed Amendment does not change that. As analyzed in Part II, the 
prerequisite of the patent linkage system under Article 18.53 is that a GDP applicant 
relies on previously-submitted test data.99 If a GDP applicant chooses to submit his 
own test data, he is not subject to the patent linkage system.100 Therefore, the PAA 
and Proposed Amendment are not flexible to a generic drug company. 
 
IV. TAIWAN’S PROPOSED PATENT LINKAGE SYSTEM 
The TPP Agreement requires a member state either to adopt a notification 
mechanism under Article 18.53(1) or to stay the issuance of marketing approval under 
Article 18.53(2).101 But, Taiwan’s implementation of Article 18.53 includes a 
notification mechanism and allows the health authority to stay the issuance of a 
GDP.102 Whether the health authority may lift the stay depends on whether the patent 
dispute surrounding a GDP application is resolved in favor of the GDP applicant.103 
Thus, Taiwan’s patent linkage system provides broader protection than what is 
required under the TPP Agreement. 
 
A. Patent Information Submission 
The proposed patent linkage system starts with the provisions concerning “patent-
related information” mentioned in Article 18.53(2) of the TPP Agreement.104 Article 
48-3 and Article 48-5 of the Proposed Amendment condition whether one may benefit 
from patent linkage on whether she timely submits patent information related to her 
NDP.105 Article 48-3, Paragraph 1 provides that “if a drug permit holder of a new drug 
thinks that it is necessary to submit the patent information of drug patents, she should 
prepare relevant documents and information and submit them to the central health 
                                                          
 97 See Regulations for Registration of Medicinal Products Art. 4 (2015). 
 98 PAA Art. 40-2, ¶ 3. 
 99 See id. 
 100 See id.  
 101 See TPP Agreement art. 18.53. 
 102 Id. 
 103 Id. 
 104 Id. 
 105 PAA Arts. 48-3, 48-5. 
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authority in forty five days starting from the next day of her receipt of a drug 
permit[.]”106 If she fails to submit the required patent information, Chapter 4-1 will 
not apply.107 
On the other hand, Article 48-5 provides that “if a drug permit holder of a new 
drug acquires an invention patent examined and issued by the patent authority after 
her drug permit was granted by the central health authority and if such invention patent 
falls within the scope of drug patents under Article 48-3, Paragraph 2, she shall follow 
[Article 48-4] to submit the patent information in forty five days starting from the next 
day of the issuance of the patent.”108 If she fails to do so, Chapter 4-1 is not 
applicable.109 
The Proposed Amendment also considers existing NDP holders’ interests.110 
Article 48-21 provides that when the Proposed Amendment becomes effective, an 
existing NDP holder may submit the required patent information under Article 48-4 
in three months from the effectiveness of the Proposed Amendment.111 
An eligible drug patent is defined in Article 48-3 as a patent claiming (a) a material; 
(b) a combination or formula; or (c) pharmaceutical use.112 The scope of “drug 
patents” under Article 48-3 makes the proposed patent linkage system TPP-Plus.113 
The category of “material” patents covers any patent that claims a single ingredient of 
an approved drug.114 The scope of “single ingredients” covers not only active 
pharmaceutical ingredients but also excipients.115 On the other hand, an eligible patent 
under the TPP Agreement is a patent claiming the approved product composed of 
active pharmaceutical ingredients and excipients.116 Hence, the Proposed Amendment 
enlarges the scope of eligible patent holders beyond what is required by the TPP 
Agreement. 
The required patent information of a drug patent is vested in Article 48-4. For each 
drug patent, a NDP holder basically has to submit three pieces of information: (a) the 
patent number; (b) the last date of the term of protection; (c) the patent owner’s name 
or title, nationality, and residence, domicile or business place.117 If a drug patent claims 
pharmaceutical use of a drug, a NDP holder has to identify claim numbers.118 If a drug 
patent is licensed exclusively and if such exclusive license is recorded in the patent 
                                                          
 106 PAA Art. 48-3, ¶ 1. 
 107 See PAA Art. 48-3, ¶ 1. 
 108 PAA Art. 48-5. 
 109 See id. 
 110 PAA Art. 48-21. 
 111 See id. 
 112 See id. 
 113 See PAA Art. 48-21. 
 114 Id. 
 115 Id. 
 116 See supra Part II.B.1. 
 117 See PAA Art. 48-4, ¶ 1. 
 118 See id.  
 
2017] ANALYSIS OF PROPOSED TPP-RELATED SYSTEM 73 
 
authority, the (c) information of the exclusive licensee is required.119 If the owner or 
exclusive licensee of a drug patent does not reside, domicile, or have a business place 
in Taiwan, the (c) information of her agent is required.120 Last, if a NDP holder is not 
the owner or exclusive licensee of the drug patent, when submitting the required patent 
information, she should acquire a consent from the owner or exclusive licensee.121 
The required patent information of a drug patent may be corrected by a NDP 
holder.122 Under Article 48-6, a NDP holder should apply for an amendment of patent 
information if any of the following conditions have occurred: (a) the patent authority 
grants and announces the extension of the term of protection; (b) the claims have been 
amended and published; (c) the revocation of the drug patent has been finalized; (d) 
the drug patent has expired; (e) the information of the patent owner, exclusive licensee, 
or agent has changed.123 If a NDP holder is not the owner or exclusive licensee of a 
drug patent, such amendment should be permitted by the patentee or exclusive 
licensee.124 Furthermore, a NDP holder is required to file an amendment in forty-five 
days from the next day of the occurrence of any of those five conditions.125 But, there 
is no negative consequence if she fails to do so. 
The public may challenge the correctness of the required patent information.126 
Article 48-7 provides that any person may notify the Taiwan FDA of any of the 
following incidents: (a) the documented drug patent has nothing to do with the 
approved drug; (b) the documented drug patent does not claim a material, combination 
or formula, or pharmaceutical use; (c) errors exist in the patent information; (d) the 
NDP holder fails to comply with Article 48-6.127 Such person should submit written 
reasons and evidence to support an Article 48-7 notification.128 Then, the Taiwan FDA 
should forward the notification to the NDP holder in twenty days from the next day of 
the filing of the notification.129 Next, the NDP holder should respond to the Taiwan 
FDA with written reasons, but the NDP holder is free to decide whether to file an 
amendment.130 In the end, the Taiwan FDA is not required to change the challenged 
information even if it is incorrect.131 Instead, the Taiwan FDA is only mandated to 
                                                          
 119 See id.  
 120 See id.  
 121 See PAA Art. 48-4, ¶ 2. 
 122 See id. 
 123 See id. 
 124 See PAA Art. 48-6, ¶ 1. 
 125 See PAA Art. 48-6, ¶ 2. 
 126 See PAA Art. 66. 
 127 See PAA Art. 48-7, ¶ 1. 
 128 See id. 
 129 See PAA Art. 48-7, ¶ 2. 
 130 See PAA Art. 48-7, ¶ 3. 
 131 See PAA Art. 48-7. 
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publish the information submitted by the challenger under Article 48-7 and the 
response submitted by the NDP holder.132 
However, it is not to say that a NDP holder can document any patents he wants. 
Under Article 100-1, “if a drug permit holder of a new drug submits patent information 
as required by Articles 48-3 to 48-6 in a way of deception or falseness to the extent 
where criminal liability is involved, he should be transferred to the judicial authority 
for further proceedings.”133 Article 100-1 indicates that the falseness of the required 
patent information may cause a NDP holder to be held criminally liable.134 But, Article 
100-1 does not specify any crimes that may be committed. 
 
B. Notification Made by a Generic Drug Permit Applicant 
Unlike the current PAA, the Proposed Amendment formally recognizes generic 
drug applications. While the Proposed Amendment does not define a “generic drug,” 
it does use the term “generic drug permit” in several provisions related to the patent 
linkage system.135 
Article 48-9 provides that “[w]hen applying for a drug permit, with respect to the 
patents documented by a [NDP] holder for the approved new drug, an applicant for a 
[GDP] should declare to the central health authority” any of the four situations.136 The 
first situation is that “no patent information is documented for such new drug.”137 The 
second situation is that “the patents corresponding to such new drug have expired.”138 
When a declaration of the first or second situation is made, a GDP will be issued after 
the Taiwan FDA completes the examination of such GDP application and concludes 
that all requirements are satisfied.139 The third situation is that “after the patents 
corresponding to such new drug expired, the drug permit is issued by the central health 
authority.”140 When a declaration of the third situation is made, even though all 
requirements are met, a GDP will not be granted until the documented patents 
expire.141 
The fourth situation is that “the patents corresponding to such new drug should be 
revoked, or the generic drug for the drug permit application does not infringe the 
patents corresponding to such new drug.”142 When a declaration of the fourth situation 
is made, the patent linkage system will be initiated. After a GDP application is filed, 
the Taiwan FDA will review whether the required data and information are 
                                                          
 132 See PAA Art. 48-8. 
 133 PAA Art. 100-1. 
 134 See id. 
 135 See generally PAA. 
 136 See PAA Art. 48-9. 
 137 See id. 
 138 See id. 
 139 See PAA Art. 48-10. 
 140 See PAA Art. 48-9. 
 141 See PAA Art. 48-11. 
 142 See PAA Art. 48-9. 
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complete.143 If the submitted data meets the requirements, the Taiwan FDA will serve 
a notification of completeness of data submission to the GDP applicant.144  
When a declaration of the fourth situation is made, Article 48-12 requires a GDP 
applicant to serve a written notification to the NDP holder and Taiwan FDA in twenty 
days starting from the next day of the GDP applicant’s receipt of the completeness 
notification.145 If the NDP holder does not own the patent or is not licensed 
exclusively, an Article 48-12 notification must also be served on the patentee or 
exclusive licensee.146 The written notification must include reasons and evidence of 
invalidity or non-infringement.147 If the GDP applicant fails to timely serve an Article 
48-12 notification, the Taiwan FDA will reject the GDP application.148 
As analyzed in Part II, the proper timing for a notification under Article 18.53(1) 
is the health authority’s granting of marketing approval.149 But, the Taiwan’s approach 
requires a notification to be delivered by a GDP applicant to a patentee or exclusive 
licensee when the GDP application is filed.150 The GDP applicant is also required to 
show why the patent at dispute is invalid or not infringed.151 That is, the burden of 
proof is imposed on the GDP applicant who is a potential patent infringer. 
 
C. Stay of Issuance of a Drug Permit to a GDP Applicant 
The Proposed Amendment introduces a mechanism where the Taiwan FDA may 
stay issuance of a drug permit to a GDP applicant. Under Article 48-13, the mechanism 
is controlled by the patentee or exclusive licensee.152 After the patentee or exclusive 
licensee receives an Article 48-12 notification, he must sue the GDP applicant for 
infringement of any documented patents in forty-five days starting from the next day 
of the receipt of the Article 48-12 notification.153 Article 48-13 further provides that 
the period of forty-five days runs from the receipt by the patentee or exclusive 
licensee, whoever receives the Article 48-12 notification later.154 The patentee or 
exclusive licensee must notify the Taiwan FDA of the filing of such law suit.155 
Meanwhile, Article 48-13 mandates the Taiwan FDA not to issue a drug permit to 
the GDP applicant in fifteen months starting from the next day of the NDP holder’s 
                                                          
 143 See PAA Art. 48-12. 
 144 See id. 
 145 See PAA Art. 48-12, ¶ 1. 
 146 See id. 
 147 See PAA Art. 48-12, ¶ 2. 
 148 See PAA Art. 48-12, ¶ 3. 
 149 TPP Agreement art. 18.53. 
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 152 See PAA Art. 48-13. 
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receipt of the Article 48-12 notification.156 But, the Taiwan FDA may issue a drug 
permit to the GDP applicant in any of the following situations157:  
(1) The patentee or exclusive licensee does not initiate a law suit during the 
required period of forty-five days. 
(2) The law suit filed after the receipt of the Article 48-12 notification is not based 
on a patent documented under Article 48-3, 48-5, or 48-21 before the GDP application. 
(3) Courts find that all patents disputed in the law suit should have been 
invalidated, or the GDP applicant wins a decision of non-infringement. 
(4) All patents stated in the declaration of a fourth situation under Article 48-9 
have been revoked by the Taiwan Intellectual Property Office. 
(5) The patentee (or exclusive licensee) and GDP applicant have agreed to settle 
the dispute. 
(6) All patents stated in the declaration of a fourth situation under Article 48-9 
have expired. 
If the patentee or exclusive licensee wins the law suit filed under Article 48-13 and 
if the winning decision is finalized in fifteen months starting from the next day of the 
NDP holder’s receipt of the Article 48-12 notification, the Taiwan FDA is obligated 
under Article 48-13 not to issue a GDP until the patent at dispute expires.158 But, a 
stay under Article 48-13 is only implemented once.159 If the patent or exclusive 
licensee sues the same GDP applicant for the same generic drug again with a different 
documented patent not brought in the previous law suit, the Taiwan FDA will not stay 
issuance of a GDP.160 
Last, while the Taiwan FDA must stay issuance of a GDP, it can continue the 
examination of the GDP application.161 Under Article 48-15, if the Taiwan FDA 
completes the examination, it should notify the GDP applicant.162 After receiving an 
Article 48-15 notification, the GDP applicant may file to the National Health 
Insurance Administration an application for inclusion of her drug product in the 
national health insurance system and for price determination163 But, the GDP applicant 
is not allowed to manufacture or import the generic drug until a GDP is issued.164 
 
D. Exclusive Sales Period 
The Proposed Amendment grants a period of exclusive sales to a GDP applicant 
who has made a declaration of the fourth situation under Article 48-9, if such applicant 
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eventually gets a GDP.165 During the exclusive sales period, the Taiwan FDA is 
prevented from granting other GDPs for the same drug.166 But, it should be noted that 
under Article 48-20 a right of exclusive sales applies only if the drug under a GDP 
was a drug of a new compound.167 If the drug was a drug of a composition with a new 
therapeutic effect or a drug of a dosage form with a new administration, a right of 
exclusive sales does not exist.168 
Under Article 48-16, a GDP holder whose data submission has been first 
considered complete by the Taiwan FDA will earn an exclusive sales period of twelve 
months.169 However, the calculation of the period does not start from the receipt of a 
GDP. Under Article 48-17, the period starts from actual sale of the products under 
such GDP.170 The exclusive GDP holder has to report the actual sale to the Taiwan 
FDA in twenty days starting from the next day of the actual sale.171 Then, the Taiwan 
FDA will determine the period including the starting date and expiration date.172 
However, in the context of multiple GDP applicants, Article 48-16 provides that if 
the Taiwan FDA determines that more than one GDP applicants complete their data 
submission on the same day, these GDP applicants will share an exclusive sales 
period.173 In addition, the calculation of the period starts from the earliest actual sale 
made by any of those GDP applicants.174 
A GDP applicant who is supposed to enjoy an exclusive sales period may lose his 
right to exclusive sales, if any of the following three situations occurs with respect to 
his GDP application175:  
(1) During the examination of the GDP application, the declaration a fourth 
situation under Article 48-9 has been withdrawn. 
(2) A notification of the completion of the examination is not received in twelve 
months starting from the next day of the completeness of the data submission. 
(3) The patentee or exclusive licensee wins the law suit filed under Article 48-13, 
and the winning decision is finalized in fifteen months starting from the next day of 
the NDP holder’s receipt of the Article 48-12 notification. 
If the first GDP applicant loses a right to exclusive sales, other following GPD 
applicants for the same drug may earn such right.176 Article 48-16 provides that the 
determination of which following GPD applicant inherits such right depends on the 
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date on which their data submission is considered complete.177 A following GDP 
applicant who gets the earliest date wins the exclusive sales period.178 
Last, Article 48-18 provides three situations where the Taiwan FDA may grant a 
GPD to other applicants without the concerns of the existing right of sales 
exclusivity.179 First, the GDP applicant who is supposed to enjoy an exclusive sales 
period fails to acquire a GDP by a deadline required by the Taiwan FDA.180 Second, 
such GDP applicant has never reported the date of actual sale.181 Third, the patents 
listed in the declaration of the fourth situation under Article 48-9 have expired.182 
The exclusive sales period seems to be negative to a pioneer drug company 
because a generic drug company may share the market. But, the exclusivity actually 
limits the competition the pioneer drug company will face. The pioneer drug company 
and its rival generic drug company co-exist without any business penetrations from 
other generic drug companies. That is an oligopoly where a small number of drug 
companies are in the market.183 Although the drug price may drop, it will not be as 
lower as what would be in perfect competition.184 Therefore, granting of an exclusive 
sales period is actually positive to a pioneer drug company. 
 
E. Anti-Competition Provision 
The Proposed Amendment mandates a duty to report an agreement among a NDP 
applicant, NDP holder, GDP applicant, GDP holder, eligible patentee or exclusive 
licensee, if such agreement involves Chapter 4-1 affairs including drug manufacturing, 
sales, and exclusive sales period.185 Article 48-19 requires parties of such agreement 
to report to the Taiwan FDA in twenty days starting from the next day of the signing 
date of such agreement.186 The way to report and the content of such report are subject 
to the regulations made by the Taiwan FDA.187 Failure to report such agreement may 
result in an administrative monetary penalty imposed on the parties to such 
agreement.188 Finally, if the Taiwan FDA determines that such agreement is more 
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likely to violate the Fair Trade Act, it will refer the case to the Fair Trade Commission 
for further proceedings.189 
 
V. CONCLUSION 
To prepare for joining the TPP Agreement, the Taiwan Government has begun to 
implement a patent linkage system required under Article 18.53 of the TPP 
Agreement. Taiwan’ approach is a pro-patentee mechanism. The mechanism allows a 
NDP holder to register patents claiming (a) a material; (b) a combination or formula; 
or (c) pharmaceutical use.190 The scope of patentees who may benefit from the 
mechanism is larger than what Article 18.53 requires. In addition, the mechanism 
requires a GDP applicant to notify the NDP holder and patentee at the time of filing 
the GDP application when the applicant asserts no patents associated with the generic 
drug are valid or infringed.191 The mechanism forces the GDP applicant to prove 
invalidity or non-infringement.192 Furthermore, the mechanism allows the Taiwan 
FDA to stay the issuance of a GDP while the patentee is suing the GDP applicant in 
the court.193 Therefore, the proposed patent linkage system may be considered as TPP-
Plus.  
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